海分枝杆菌对加替沙星、吉米沙星、左氧氟沙星、利奈唑胺、莫西沙星、泰利霉素和奎奴普丁-达福普汀（Synercid）的敏感性与其对参考大环内酯类和喹诺酮类药物的敏感性比较。
Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones.
作者信息
Bråbäck Martin, Riesbeck Kristian, Forsgren Arne
机构信息
Department of Medical Microbiology, Lund University, University Hospital, S-205 02 Malmö, Sweden.
出版信息
Antimicrob Agents Chemother. 2002 Apr;46(4):1114-6. doi: 10.1128/AAC.46.4.1114-1116.2002.
Abstract
The susceptibility pattern of Mycobacterium marinum was determined. Quinupristin-dalfopristin and telithromycin were less active than clarithromycin. Linezolid showed good antimicrobial activity at clinically achievable concentrations. Gatifloxacin, levofloxacin, and moxifloxacin displayed activities similar to those of ciprofloxacin. Gemifloxacin was less active. The Etest method showed variable agreement with the reference method.
摘要
测定了海分枝杆菌的药敏模式。奎奴普丁-达福普汀和泰利霉素的活性低于克拉霉素。利奈唑胺在临床可达到的浓度下显示出良好的抗菌活性。加替沙星、左氧氟沙星和莫西沙星的活性与环丙沙星相似。吉米沙星的活性较低。Etest法与参考方法的一致性存在差异。
相似文献
1
Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones.海分枝杆菌对加替沙星、吉米沙星、左氧氟沙星、利奈唑胺、莫西沙星、泰利霉素和奎奴普丁-达福普汀（Synercid）的敏感性与其对参考大环内酯类和喹诺酮类药物的敏感性比较。
Antimicrob Agents Chemother. 2002 Apr;46(4):1114-6. doi: 10.1128/AAC.46.4.1114-1116.2002.
2
Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.人型支原体、肺炎支原体和解脲脲原体对GAR-936、达福普汀、地红霉素、依维霉素、加替沙星、利奈唑胺、莫西沙星、奎奴普丁-达福普汀和泰利霉素的敏感性与其对参考大环内酯类、四环素类和喹诺酮类药物的敏感性比较。
Antimicrob Agents Chemother. 2001 Sep;45(9):2604-8. doi: 10.1128/AAC.45.9.2604-2608.2001.
3
In vitro activity of quinupristin/dalfopristin, linezolid, telithromycin and comparator antimicrobial agents against 13 species of coagulase-negative staphylococci.奎奴普丁/达福普汀、利奈唑胺、泰利霉素及对照抗菌药物对13种凝固酶阴性葡萄球菌的体外活性
J Antimicrob Chemother. 2002 Dec;50(6):933-8. doi: 10.1093/jac/dkf241.
4
Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae.青霉素G、左氧氟沙星、莫西沙星、泰利霉素、普那霉素、奎奴普丁-达福普汀和利奈唑胺对左氧氟沙星中介及耐药肺炎链球菌的体外比较活性
Clin Microbiol Infect. 2002 Oct;8(10):680-3. doi: 10.1046/j.1469-0691.2002.00455.x.
5
In vitro activity of linezolid, synercid and telithromycin against genetically defined high level fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus.利奈唑胺、奎奴普丁/达福普汀和泰利霉素对基因明确的高水平氟喹诺酮耐药耐甲氧西林金黄色葡萄球菌的体外活性。
Int J Antimicrob Agents. 2002 Jul;20(1):61-4. doi: 10.1016/s0924-8579(02)00107-3.
6
In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations.泰利霉素、利奈唑胺和奎奴普丁-达福普汀对因核糖体突变而对大环内酯类耐药的肺炎链球菌的体外活性。
Antimicrob Agents Chemother. 2004 Aug;48(8):3169-71. doi: 10.1128/AAC.48.8.3169-3171.2004.
7
In vitro activity of telithromycin, quinupristin/dalfopristin, linezolid and comparator antimicrobial agents against Staphylococcus aureus clinical isolates.泰利霉素、奎奴普丁/达福普汀、利奈唑胺及对照抗菌药物对金黄色葡萄球菌临床分离株的体外活性
J Chemother. 2004 Jun;16(3):230-7. doi: 10.1179/joc.2004.16.3.230.
8
In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria.新型氟喹诺酮类药物和利奈唑胺对非结核分枝杆菌的体外活性
Int J Antimicrob Agents. 2003 Jun;21(6):585-8. doi: 10.1016/s0924-8579(03)00048-7.
9
Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.莫西沙星、曲伐沙星、奎奴普丁/达福普汀及利奈唑胺对葡萄球菌的体外活性比较
J Antimicrob Chemother. 1999 Apr;43(4):569-73. doi: 10.1093/jac/43.4.569.
10
Activities of clindamycin, synercid, telithromycin, linezolid, and mupirocin against Gram-positive coccal strains resistant to erythromycin in Korea.
Arch Pharm Res. 2007 Jul;30(7):840-3. doi: 10.1007/BF02978834.
引用本文的文献
1
hand infection: a case report and literature review.手部感染：一例病例报告及文献综述
Front Med (Lausanne). 2024 Aug 9;11:1433153. doi: 10.3389/fmed.2024.1433153. eCollection 2024.
2
Facile green synthesis of silver nanoparticles derived from the medicinal plant and its biological activity against species.源自药用植物的银纳米颗粒的简便绿色合成及其对物种的生物活性。
Heliyon. 2024 May 10;10(10):e31116. doi: 10.1016/j.heliyon.2024.e31116. eCollection 2024 May 30.
3
: A Case-Based Narrative Review of Diagnosis and Management.基于病例的诊断与管理叙述性综述
Microorganisms. 2023 Jul 13;11(7):1799. doi: 10.3390/microorganisms11071799.
4
Unusual Mycobacterium marinum Infection in a Heart Transplant Recipient: A Case Report.心脏移植受者中罕见的海分枝杆菌感染：一例报告
Cureus. 2022 Dec 10;14(12):e32387. doi: 10.7759/cureus.32387. eCollection 2022 Dec.
5
Unusual presentation of carpal tunnel syndrome due to infection of hand.手部感染导致腕管综合征的不常见表现。
BMJ Case Rep. 2022 Dec 19;15(12):e251692. doi: 10.1136/bcr-2022-251692.
6
Antibiotic Susceptibility of Mycobacteria Isolated from Ornamental Fish.从观赏鱼中分离出的分枝杆菌的抗生素敏感性
J Vet Res. 2022 Mar 25;66(1):69-76. doi: 10.2478/jvetres-2022-0011. eCollection 2022 Mar.
7
Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease.非结核分枝杆菌病的诊断与治疗方法
J Clin Tuberc Other Mycobact Dis. 2021 May 8;24:100244. doi: 10.1016/j.jctube.2021.100244. eCollection 2021 Aug.
8
Deep infection with : successful treatment of a frequently misdiagnosed disease.深部感染伴：一种常被误诊疾病的成功治疗。
BMJ Case Rep. 2019 Aug 28;12(8):e229663. doi: 10.1136/bcr-2019-229663.
9
RepTB: a gene ontology based drug repurposing approach for tuberculosis.RepTB：一种基于基因本体论的结核病药物再利用方法。
J Cheminform. 2018 May 21;10(1):24. doi: 10.1186/s13321-018-0276-9.
10
Skin and Soft Tissue Infections Due to Nontuberculous Mycobacteria.非结核分枝杆菌引起的皮肤和软组织感染
Curr Infect Dis Rep. 2018 Mar 19;20(4):6. doi: 10.1007/s11908-018-0611-3.
本文引用的文献
1
2
Antimicrobial susceptibility of Mycobacterium marinum determined by E-test and agar dilution.采用E试验和琼脂稀释法测定海分枝杆菌的抗菌药敏性。
Scand J Infect Dis. 2001;33(8):585-8. doi: 10.1080/00365540110026773.
3
Activities of linezolid against rapidly growing mycobacteria.利奈唑胺对快速生长分枝杆菌的活性。
Antimicrob Agents Chemother. 2001 Mar;45(3):764-7. doi: 10.1128/AAC.45.3.764-767.2001.
4
Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.利奈唑胺（PNU-100766）与苯唑西林-双氯西林治疗复杂性皮肤及软组织感染的随机对照研究
Antimicrob Agents Chemother. 2000 Dec;44(12):3408-13. doi: 10.1128/AAC.44.12.3408-3413.2000.
5
Antibiotic susceptibility pattern of Mycobacterium marinum.海分枝杆菌的抗生素敏感性模式
Antimicrob Agents Chemother. 2000 Nov;44(11):3133-6. doi: 10.1128/AAC.44.11.3133-3136.2000.
6
In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4.与克拉霉素相比，酮内酯类药物泰利霉素（HMR 3647）和HMR 3004在pH值为6.8和7.4时对缓慢生长分枝杆菌的体外活性。
Antimicrob Agents Chemother. 2000 Oct;44(10):2848-52. doi: 10.1128/AAC.44.10.2848-2852.2000.
7
In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs.六种氟喹诺酮类药物对250株对一线抗结核药物敏感或耐药的结核分枝杆菌临床分离株的体外活性。
Antimicrob Agents Chemother. 2000 Sep;44(9):2567-8. doi: 10.1128/AAC.44.9.2567-2568.2000.
8
Linezolid.利奈唑胺
Drugs. 2000 Apr;59(4):815-27; discussion 828. doi: 10.2165/00003495-200059040-00007.
9
In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.新型广谱8-甲氧基氟喹诺酮加替沙星的体外抗菌谱
J Antimicrob Chemother. 2000 Apr;45(4):437-46. doi: 10.1093/jac/45.4.437.
10
In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials.快速生长分枝杆菌对泰利霉素（HMR 3647）及其他七种抗菌药物的体外敏感性
Antimicrob Agents Chemother. 2000 Jan;44(1):181-2. doi: 10.1128/AAC.44.1.181-182.2000.
Zotero 插件